Result of Annual General Meeting

RNS Number : 8437Q

Oxford Biomedica PLC

23 June 2020

 

Oxford Biomedica

Result of Annual General Meeting

Oxford, UK - 23 June 2020: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in Oxford. 

In accordance with Listing Rule 9.6.18, the following resolutions are those which were passed at the meeting concerning special business:

· Resolution 13: to authorise the Directors, pursuant to section 551 of the Companies Act 2006, to allot shares (or grant rights to subscribe for, or convert securities into, shares), up to an aggregate nominal amount of two-thirds of the presently issued shares, one-third of which may only be used in connection with a rights issue in favour of shareholders;

· Resolution 14: to authorise the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares;

· Resolution 15: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares in connection with an acquisition or specified capital investment;

· Resolution 16: to adopt new articles of association in order to update the Company's current articles of association, which were adopted in 2010; and

· Resolution 17: to permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxb.com

Copies of the document setting out the above resolutions passed at the 2020 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism

The results of the proxy voting in advance of the meeting are shown below. On the Record Date (19 June 2020) there were 77,002,369 ordinary shares of 50 pence each in issue, each carrying one vote per share.

Resolution	Votes For	Votes at Chairman's Discretion	Votes at other proxy Discretion	Votes Against	Votes Withheld*	Total votes cast	Result
Ordinary resolutions
1	49,841,735	917	0	0	113,171	49,842,652	Passed
2	48,970,356	917	0	909,694	74,856	49,880,967	Passed
3	47,679,014	917	0	2,202,867	73,024	49,882,798	Passed
4							WITHDRAWN
5	49,752,318	917	0	131,635	70,953	49,884,870	Passed
6	49,751,723	917	0	132,230	70,953	49,884,870	Passed
7	46,661,012	917	0	3,222,941	70,953	49,884,870	Passed
8	47,680,935	917	0	2,203,017	70,953	49,884,869	Passed
9	48,322,433	917	0	1,561,520	70,953	49,884,870	Passed
10	48,322,702	917	0	1,561,277	70,927	49,884,896	Passed
11	48,872,224	917	0	7,169	75,513	49,880,310	Passed
12	49,871,544	917	0	9,284	74,078	49,881,745	Passed
13	47,858,386	917	0	592,553	1,503,967	48,451,856	Passed
Special resolutions
14	48,112,773	917	0	336,725	1,505,408	48,450,415	Passed
15	48,111,711	917	0	337,790	1,505,405	48,450,418	Passed
16	49,878,294	917	0	1,370	75,242	49,880,581	Passed
17	49,177,732	917	0	705,017	72,157	49,883,666	Passed

* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.

-Ends-

Enquiries:
Oxford Biomedica plc John Dawson, Chief Executive Officer Stuart Paynter, Chief Financial Officer Catherine Isted, Head of Corporate Development & IR	T: [phone] T: [phone] T: [phone] / E: [e-mail]
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal	T: [phone]

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a Clinical and Commercial Supply Agreement with AstraZeneca for manufacture of the adeno based COVID-19 vaccine candidate, AZN1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. Further information is available at  www.oxb.com

 

END

 

 

RAGKKNBQPBKDBAB